Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis [2]

Acta Dermato-Venereologica

Volumn 81, Issue 6, 2001, Pages 429-430

  Friedrich, Markus ^a   Sterry, Wolfram ^a   Klein, Anja ^a   Rückert, René ^a   Döcke, Wolf Dietrich ^a   Asadullah, Khusru ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM; FUMARIC ACID; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0035699719     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155501317208408     Document Type: Letter

References (9)

1. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use
2. Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study (German Multicentre Study)
3. Influence of monomethylfumarate on monocytic cytokine formation - Explanation for adverse and therapeutic effects in psoriasis?
4. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
5. Kinetics of intravenous and oral pentoxifylline in healthy subjects
6. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: Efficacy in a randomized, placebo-controlled trial
7. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
8. Is pentoxifylline effective in the treatment of psoriasis?
9. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis